Publications du centre

Liste des publications

Publications du département d'ophtalmologie

Bienvenue sur la page dédiée aux publications scientifiques du département d'ophtalmologie du centre médical des Aravis. Notre équipe médicale s'investit activement dans la recherche et l'innovation afin d'améliorer constamment la prise en charge de nos patients. Nos travaux portent sur un large éventail de thématiques, notamment :

Domaines d'expertise

Les maladies de la cornée, telles que le kératocône, et les techniques chirurgicales associées (greffe de cornée, etc.).
Les pathologies rétiniennes, comme la DMLA ou le décollement de la rétine, avec une expertise particulière dans les traitements par injections intravitréennes et la chirurgie vitréo-rétinienne.
L'épidémiologie et la santé publique en ophtalmologie, en utilisant des bases de données nationales pour analyser les tendances et les facteurs de risque de différentes maladies oculaires.
L'impact des technologies numériques sur la santé oculaire, notamment l'utilisation de la télémédecine pour le dépistage de la rétinopathie diabétique.

Nous sommes fiers de partager ici nos contributions à l'avancement des connaissances en ophtalmologie. N'hésitez pas à consulter nos publications pour en savoir plus sur nos domaines d'expertise et nos recherches en cours.

Afficher tous

2022

Gabrielle, Pierre-Henry; Baudin, Florian; Ghezala, Ines Ben; Meillon, Cyril; Bron, Alain Marie; Arnould, Louis; Creuzot-Garcher, Catherine

Bilateral acute macular neuroretinopathy in a young woman after the first dose of Oxford-AstraZeneca COVID-19 vaccine Article de journal

Dans: Am. J. Ophthalmol. Case Rep., vol. 25, no. 101281, p. 101281, 2022.

Résumé | BibTeX | Étiquettes: AMN; Acute macular neuroretinopathy; COVID-19; Side effect; Vaccination

@article{Gabrielle2022-go,

title = {Bilateral acute macular neuroretinopathy in a young woman after 

 the first dose of Oxford-AstraZeneca COVID-19 vaccine},

author = {Pierre-Henry Gabrielle and Florian Baudin and Ines Ben Ghezala and Cyril Meillon and Alain Marie Bron and Louis Arnould and Catherine Creuzot-Garcher},

year  = {2022},

date = {2022-03-01},

journal = {Am. J. Ophthalmol. Case Rep.},

volume = {25},

number = {101281},

pages = {101281},

publisher = {Elsevier BV},

abstract = {PURPOSE: To report a case of bilateral acute macular 

 neuroretinopathy following the first dose of Oxford-AstraZeneca 

 COVID-19 (coronavirus disease 2019) vaccine in a young, 

 Caucasian, and healthy woman. OBSERVATIONS: A 25-year-old 

 Caucasian female patient presented to the ophthalmology 

 department of Dijon University Hospital with a 3-week history of 

 black spots and paracentral scotoma in both eyes. She had no 

 past medical history and was using the combined 

 estrogen-progestin oral contraceptive (COC). These symptoms 

 occurred 24 h after receiving the first Oxford-AstraZeneca 

 COVID-19 vaccination dose. The ophthalmologic signs were 

 preceded a few hours earlier by fever and flu-like symptoms. 

 Ophthalmologic examination revealed a preserved visual acuity 

 with a quiet anterior segment and normal fundus in both eyes. 

 Findings on multimodal retinal imaging, particularly 

 near-infrared reflectance (NIR) and optical coherence tomography 

 (OCT) imaging, were classical of an acute macular 

 neuroretinopathy in both eyes. CONCLUSIONS AND IMPORTANCE: 

 COVID-19 vaccination is justified as an essential public health 

 measure. Acute macular neuroretinopathy may occur in patient 

 receiving a COVID-19 vaccination dose. Further reports are 

 needed to confirm this association. Physicians should be aware 

 of this complication and request an eye examination with at 

 least OCT or NIR imaging in the case of any visual symptoms 

 after vaccination, notably in young women using COC.},

keywords = {AMN; Acute macular neuroretinopathy; COVID-19; Side effect;   Vaccination},

pubstate = {published},

tppubtype = {article}

}

Fermer

Explorer

Recherche

Gabrielle, Pierre-Henry; Baudin, Florian; Ghezala, Ines Ben; Meillon, Cyril; Bron, Alain Marie; Arnould, Louis; Creuzot-Garcher, Catherine

Bilateral acute macular neuroretinopathy in a young woman after the first dose of Oxford-AstraZeneca COVID-19 vaccine Article de journal

Dans: Am. J. Ophthalmol. Case Rep., vol. 25, no. 101281, p. 101281, 2022.

Résumé | BibTeX

@article{Gabrielle2022-go,

title = {Bilateral acute macular neuroretinopathy in a young woman after 

 the first dose of Oxford-AstraZeneca COVID-19 vaccine},

author = {Pierre-Henry Gabrielle and Florian Baudin and Ines Ben Ghezala and Cyril Meillon and Alain Marie Bron and Louis Arnould and Catherine Creuzot-Garcher},

year  = {2022},

date = {2022-03-01},

journal = {Am. J. Ophthalmol. Case Rep.},

volume = {25},

number = {101281},

pages = {101281},

publisher = {Elsevier BV},

abstract = {PURPOSE: To report a case of bilateral acute macular 

 neuroretinopathy following the first dose of Oxford-AstraZeneca 

 COVID-19 (coronavirus disease 2019) vaccine in a young, 

 Caucasian, and healthy woman. OBSERVATIONS: A 25-year-old 

 Caucasian female patient presented to the ophthalmology 

 department of Dijon University Hospital with a 3-week history of 

 black spots and paracentral scotoma in both eyes. She had no 

 past medical history and was using the combined 

 estrogen-progestin oral contraceptive (COC). These symptoms 

 occurred 24 h after receiving the first Oxford-AstraZeneca 

 COVID-19 vaccination dose. The ophthalmologic signs were 

 preceded a few hours earlier by fever and flu-like symptoms. 

 Ophthalmologic examination revealed a preserved visual acuity 

 with a quiet anterior segment and normal fundus in both eyes. 

 Findings on multimodal retinal imaging, particularly 

 near-infrared reflectance (NIR) and optical coherence tomography 

 (OCT) imaging, were classical of an acute macular 

 neuroretinopathy in both eyes. CONCLUSIONS AND IMPORTANCE: 

 COVID-19 vaccination is justified as an essential public health 

 measure. Acute macular neuroretinopathy may occur in patient 

 receiving a COVID-19 vaccination dose. Further reports are 

 needed to confirm this association. Physicians should be aware 

 of this complication and request an eye examination with at 

 least OCT or NIR imaging in the case of any visual symptoms 

 after vaccination, notably in young women using COC.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

Fermer